Literature DB >> 12745258

Mechanism of binding of warfarin enantiomers to recombinant domains of human albumin.

S M Twine1, M G Gore, P Morton, B C Fish, A G Lee, J M East.   

Abstract

Domain fragments of human serum albumin corresponding to domains 1 and 2 (D12) and domains 2 and 3 (D23) were expressed in yeast. The kinetics of warfarin binding to these fragments were investigated using stopped-flow fluorescence spectroscopy. Binding can be characterized by a two-step process, a rapid diffusion-controlled step and a slower rate-limiting step in which a stable drug-protein complex is formed. The equilibrium constant for step 1 is greater for both D12 and D23 than for albumin, probably as a result of reduced steric hindrance offered by the domain fragments. Binding step 2, thought to be the result of a conformational change as warfarin is accommodated by the protein, is faster for D12 and D23. Albumin and the domain fragments show an increased preference for the R enantiomer, but the preference is particularly enhanced for domain fragment D12. These preferences can largely be explained by the domains having different rates for step 2 of the binding process.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12745258     DOI: 10.1016/s0003-9861(03)00173-5

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  7 in total

1.  Stereoselective binding of mexiletine and ketoprofen enantiomers with human serum albumin domains.

Authors:  Da Shi; Yin-xiu Jin; Yi-hong Tang; Hai-hong Hu; Si-yun Xu; Lu-shan Yu; Hui-di Jiang; Su Zeng
Journal:  Acta Pharmacol Sin       Date:  2012-05       Impact factor: 6.150

2.  Functional analysis of recombinant human serum albumin domains for pharmaceutical applications.

Authors:  Sadaharu Matsushita; Yu Isima; Victor Tuan Giam Chuang; Hiroshi Watanabe; Sumio Tanase; Tomu Maruyama; Masaki Otagiri
Journal:  Pharm Res       Date:  2004-10       Impact factor: 4.200

3.  Noncompetitive peak decay analysis of drug-protein dissociation by high-performance affinity chromatography.

Authors:  Jianzhong Chen; John E Schiel; David S Hage
Journal:  J Sep Sci       Date:  2009-05       Impact factor: 3.645

4.  A comparative analysis on the binding characteristics of various mammalian albumins towards a multitherapeutic agent, pinostrobin.

Authors:  Shevin R Feroz; Rumana A Sumi; Sri N A Malek; Saad Tayyab
Journal:  Exp Anim       Date:  2014-12-16

5.  Probing the interaction of a therapeutic flavonoid, pinostrobin with human serum albumin: multiple spectroscopic and molecular modeling investigations.

Authors:  Shevin R Feroz; Saharuddin B Mohamad; Zarith S D Bakri; Sri N A Malek; Saad Tayyab
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

Review 6.  Stereoselective binding of chiral drugs to plasma proteins.

Authors:  Qi Shen; Lu Wang; Hui Zhou; Hui-di Jiang; Lu-shan Yu; Su Zeng
Journal:  Acta Pharmacol Sin       Date:  2013-07-15       Impact factor: 6.150

7.  An albumin-derived peptide scaffold capable of binding and catalysis.

Authors:  Immacolata Luisi; Silvia Pavan; Giampaolo Fontanive; Alessandro Tossi; Fabio Benedetti; Adriano Savoini; Elisa Maurizio; Riccardo Sgarra; Daniele Sblattero; Federico Berti
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.